Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Successful outcome of Voluntary Harmonisation Procedure for clinical trials in Germany

10.04.2012
Three years ago, the Voluntary Harmonisation procedure (VHP) started under the auspices of the Paul-Ehrlich-Institut (PEI). The procedure enables applicants to process authorisations of clinical trials in several European countries simultaneously.

The situation was reviewed after three years and showed a positive outcome: The time that elapses before a multinational clinical trial is authorised in all participating EU countries could be reduced to less than three months. Reports on previous experience and further steps planned by experts of the PEI can be found in the online edition of Nature Reviews Drug Discovery of 10 April 2012 (doi:10.1038/nrd3202-c2)


Time for authorisation of multinational clinical trials - changes after start of VHP. Photo: Paul-Ehrlich-Institut

The development of new and innovative medicinal products is a long and tedious process. After the preclinical phase of development, potential medicinal products have to be tested for their safety and efficacy in a number of clinical trials. In each European country where a clinical trial is planned to be performed, such a clinical trial requires a national authorisation.

If a clinical trial was to be performed in more than one European country, this meant for a long time that it had to undergo the entire procedure of validation, assessment, grounds for non-acceptance/reply, and authorisation/rejection right from the start. In the case of multinational trials with more than ten member states, it could easily take more than one year before the authorisation was obtained in all countries.

The 'Clinical Trials Facilitation Group' (CTFG), a working group of the HMA ('Heads of Medicines Agencies'), decided to remedy the situation. With the experts of the Paul-Ehrlich-Institut (PEI) being in charge, the group developed a procedure which presents a major progress both for the applicants and for the medicines agencies in Europe: The 'Voluntary Harmonisation Procedure‘ (VHP). Since March 2009 the CTFG has offered applicants who intend to perform a clinical trial in three or more EU member states the opportunity to start a single authorisation procedure in these countries.

"The verification and evaluation of clinical trials is of central importance for the development of new medicinal products. To harmonise these procedures in Europe, thus assuring a more rapid and at the same time more thorough evaluation, is a major concern for us at the PEI. I am very happy that the Paul-Ehrlich-Institut assumed a leading role in this process", said Professor Klaus Cichutek, the president of the Paul-Ehrlich-Institut.

A current evaluation shows that the procedure has in fact clearly accelerated the authorisation of multinational clinical studies: In 2011, the average period required until the authorisation of a multinational clinical trial was obtained amounted to only 82 day. Previously, it took up to several months or even one year. The actual harmonisation procedure, on the other hand takes only 50 days on average. Applicants are required to apply for an authorisation in the individual countries in which the study is to be conducted within 20 days following a favourable opinion. The deadline for such cases is now only ten days, which is feasible since all scientific questions have already been answered in the new harmonised procedure. The time period required for obtaining an authorisation of multinational clinical trials could be reduced from 124 days in the first year to currently 82 days within three years thanks to the fact that the harmonisation procedure has already undergone several revisions.– an advantage of this voluntary procedure, which requires no change in the law, and in which useful changes can be implemented on a short-term basis.

"The procedure is an important simplification for applicants and medicines agencies that assess the medicinal products. The procedures themselves are accelerated, resources of the parties involved are used in an optimum manner, and are not overburdened by double work" explained Dr Hartmut Krafft, chairman of the CTFG. This statement made in his role as an expert should be correct, since experts of the PEI coordinate all harmonisation procedures, regardless of whether the clinical trials are performed in Germany or not.

The number of applications is on the increase: In 2009, 26 applications were made. In 2011, this figure was 85, and the number is increasing further. Altogether, 170 applications have been made so far. Whereas after the introduction of VHP, the procedure was at first used by university institutions and small businesses, it is now also appreciated by large pharmaceutical companies – including companies outside Europe: More than 40% of the applications with office in the USA.

The European Commission, too, deems it necessary to harmonise the procedures. For mid-2012, a draft for a new Directive on clinical trials is expected.

Original publication:
Krafft H, Bélorgey C, Szalay G.: Experience and further development with the Voluntary Harmonization Procedure for multinational clinical trials in the European Union. 2012, doi:10.1038/nrd3202-c2

Dr. Susanne Stöcker | idw
Further information:
http://www.pei.de/
http://www.nature.com/nrd/journal/vaop/ncurrent/full/nrd3202-c2.html

More articles from Health and Medicine:

nachricht Radioisotope couple for tumor diagnosis and therapy
14.05.2019 | Kanazawa University

nachricht Therapy Optimisation by Analysing the Genome
13.05.2019 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

Im Focus: A step towards probabilistic computing

Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future

When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...

Im Focus: Recording embryonic development

Scientists develop a molecular recording tool that enables in vivo lineage tracing of embryonic cells

The beginning of new life starts with a fascinating process: A single cell gives rise to progenitor cells that eventually differentiate into the three germ...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Discovering unusual structures from exception using big data and machine learning techniques

17.05.2019 | Materials Sciences

ALMA discovers aluminum around young star

17.05.2019 | Physics and Astronomy

A new iron-based superconductor stabilized by inter-block charger transfer

17.05.2019 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>